Hexarelin
Hexarelin (Examorelin)
Hexarelin (Examorelin) is a synthetic hexapeptide GHRP and the most potent GH secretagogue in the GHRP class. It produces the largest GH pulses of any GHRP at equivalent doses, but also the most significant receptor desensitisation with chronic use and meaningful cortisol and prolactin elevation. Uniquely among GHRPs, Hexarelin has direct cardioprotective effects via cardiac GHSR-1a and CD36 receptor activation — independent of its GH-releasing activity.
Mechanism of Action
Hexarelin activates GHSR-1a with exceptionally high potency, producing GH pulse amplitudes that exceed GHRP-2 and GHRP-6 at equivalent doses. It also acts at the hypothalamic level to suppress somatostatin, contributing to its superior pulse magnitude.
Uniquely, Hexarelin has been shown to exert direct cardioprotective effects through two cardiac receptor pathways: GHSR-1a activation in cardiomyocytes promotes cell survival after ischaemia, and CD36 receptor activation (a scavenger receptor) reduces cardiac lipid accumulation. These effects occur independently of GH release and have been confirmed in cardiomyopathy models.
The most significant limitation of Hexarelin is rapid receptor desensitisation. GHSR-1a downregulates after 4–6 weeks of continuous use, reducing GH pulse amplitude progressively. This mandates cycle protocols with adequate off-periods to restore receptor sensitivity.
Research Evidence
Hexarelin has Phase 1/2 clinical data including cardiac research. Its direct cardioprotective mechanism is one of the most distinctive features of any GHRP. Research also supports its use in GH deficiency testing.
Hexarelin Exerts Cardioprotective Effects Independent of GH Release
Hexarelin reduced infarct size, improved cardiac function, and decreased cardiomyocyte apoptosis in ischaemia-reperfusion models even in GH-deficient animals — confirming direct cardiac receptor-mediated protection independent of the GH axis.
Hexarelin Phase 2: Cardiac Function in GH-Deficient Adults
Hexarelin administration to GH-deficient adults produced significant improvements in cardiac function parameters (ejection fraction, cardiac output) beyond what GH replacement alone achieved, supporting a direct cardiac mechanism.
Typical Research Protocol
Hexarelin's potency means lower doses may be effective. Strict cycle protocols (4–6 weeks on, 4+ weeks off) are necessary to prevent progressive receptor desensitisation. For GH optimisation, CJC-1295 + Ipamorelin is generally preferred for long-term use due to better sustained response.
Safety Profile
Reported Side Effects
- Cortisol elevation (significant at higher doses)
- Prolactin increase
- Rapid receptor desensitisation
- Water retention
- Appetite increase
- Fatigue
Contraindications
- Active malignancy
- Cardiac conditions (paradoxical concern despite cardiac data — consult cardiologist)
- Pregnancy
- Epilepsy
- Hypothyroidism
Published Research
293 indexed PubMed papers reference Hexarelin. The 20 most recent are listed below.
- Histopathological and immunohistochemical characterization of MPTP-associated pancreatic injury and its attenuation by Hexarelin in mice.
- Protective and restorative effects of hexarelin on MPTP-induced lung injury in mice.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
- Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.
- Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator.
- Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.
- Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein.
- Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models.
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
- Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats.
- Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.
- Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice.
- Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.
- SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.
- Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.
- The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin.
- Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.
Common Research Stacks
Frequently Asked Questions
Is Hexarelin the most powerful GHRP?
Yes — among the classic GHRPs (GHRP-2, GHRP-6, Ipamorelin, Hexarelin), Hexarelin produces the largest GH pulses at equivalent doses due to its high GHSR-1a potency and dual hypothalamic-pituitary action. However, this potency comes with the greatest receptor desensitisation, strongest cortisol/prolactin co-stimulation, and least forgiving side effect profile.
What makes Hexarelin unique from other GHRPs?
Hexarelin's direct cardioprotective effects via CD36 and cardiac GHSR-1a receptors are unique in the GHRP class. It protects against myocardial ischaemia-reperfusion injury independently of GH release — a property not shared by GHRP-2, GHRP-6, or Ipamorelin. This cardiac mechanism has generated research interest for heart failure and cardiac recovery applications beyond its GH secretagogue role.
How quickly does Hexarelin cause receptor desensitisation?
Measurable GHSR-1a desensitisation typically begins within 2–4 weeks of continuous twice-daily use, with GH pulse amplitude declining progressively. After 6–8 weeks of continuous use, GH responses may be 50–70% lower than at baseline. Off periods of 4–8 weeks are required to restore receptor sensitivity. This desensitisation is more pronounced than with Ipamorelin.
Can Hexarelin be used for cardiac conditions?
The cardiac research on Hexarelin is genuinely compelling — Phase 2 data showed improvements in cardiac function beyond GH replacement alone in GH-deficient adults with cardiac compromise. However, using unregulated research-grade Hexarelin for cardiac conditions outside a clinical trial is not recommended. The cardiac benefits need clinical trial validation before medical use. Discuss with a cardiologist specialising in peptide research if considering cardiac applications.
What is the right dose to minimise cortisol?
At doses of 100 mcg, Hexarelin's cortisol stimulation is modest. At 200 mcg, cortisol elevation becomes meaningful. At ≥300 mcg, ACTH/cortisol co-stimulation is significant. The typical research approach caps Hexarelin at 100–200 mcg twice daily. Given its superior potency, 100 mcg Hexarelin may produce comparable GH response to 200 mcg GHRP-2, making dose discipline important.
Key Research References
- Torsello A et al. (2002). Hexarelin and the cardiovascular system. Eur J Pharmacol.
- Ghigo E et al. (1997). Hexarelin and cardiac function in GH deficiency. J Clin Endocrinol Metab.
Explore more Growth Hormone research compounds
Browse Growth Hormone →